COVID-19
Here’s a look at Pfizer-BioNTech, Novavax and the COVID-19 vaccine’s sales, approval in children, additional trials, potential of booster shots, and more.
In 2020, “herd immunity” was the mythical goal set forth in the hearts and minds of a struggling population, waiting on a vaccine to return us to normal. Now experts are saying herd immunity with COVID-19 may well be impossible.
Pfizer reported its first-quarter 2021 revenues of $14.6 billion, an impressive 42% operational growth.
Should this antibody continue to prove to be safe and effective in clinical studies, it will replace the previously authorized bamlanivimab, which has since been sidelined due to the rise of viral variants that diminished its effectiveness.
Please check out the biopharma industry’s COVID-19 stories that are trending for May 4, 2021.
Next year, people are likely to need an annual COVID-19 vaccination just like they need an annual flu shot.
The U.S. FDA is expected to give the go-ahead for Pfizer and BioNTech’s COVID-19 vaccine for adolescents ages 12 and older within the week.
AstraZeneca’s COVID-19 vaccine road to approval has been anything but smooth.
A study found in India that the existing COVID-19 vaccines should be effective against the Indian variant, not just the Pfizer-BioNTech vaccine.
Battered by vaccine manufacturing mishaps that led to the contamination of 15 million doses of the Johnson & Johnson vaccine, Emergent BioSolutions is shaking up its leadership to ensure such errors do not occur again.
PRESS RELEASES